<DOC>
	<DOCNO>NCT02511353</DOCNO>
	<brief_summary>In western Kenya prevalence malaria &lt; 5 year old fall 70 % 1997 40 % 2008 , stagnate . Innovative approach need continue towards elimination . Ivermectin broad spectrum antiparasitic endectocide widely use control onchocerciasis lymphatic filariasis dose 150-200 mcg/kg . Ivermectin dose potent , short-lived effect 6-11 day mosquito survival , egg-laying , parasite sporogony . Higher dos need prolong mosquitocidal effect . Previous study show ivermectin well tolerate safe even 2,000 mcg/kg . This dose finding study evaluate transmission block effect high-dose ivermectin define optimal dose future use ivermectin combination artemisinin-based combination therapy ( ACT ) mass drug administration ( MDA ) . It explore research question global relevance . A prolonged transmission block effect ivermectin could substantial consequence malaria control next decade . The result expect inform national malaria control program malaria endemic country , inform WHO guideline , contribute regulatory process .</brief_summary>
	<brief_title>Efficacy Safety High-dose Ivermectin Reducing Malaria Transmission : A Dose Finding Study</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Symptomatic , uncomplicated Plasmodium falciparum infection Positive malaria microscopy malaria RDT ( pLDH ) Age : 1850 year Provide write informed consent Agree able travel clinic day : 1 , 2 , 7 , 10 , 14 , 21 , 28 Signs symptom severe malaria Unable provide write informed consent For woman : pregnancy lactation Hypersensitivity ivermectin DP QTc &gt; 460 m ECG Body Mass Index ( BMI ) 16 32 kg/m2 Haemoglobin concentration 9 g/dL Taken ivermectin last month Taken dihydroartemisininpiperaquine last 12 week Loa loa assess travel history Angola , Cameroon , Chad , Central African Republic , Congo , DR Congo , Equatorial Guinea , Ethiopia , Gabon , Nigeria Sudan History and/or symptom indicate chronic illness Current use tuberculosis antiretroviral medication Previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>malaria</keyword>
	<keyword>plasmodium</keyword>
	<keyword>dihydroartemisinin-piperaquine</keyword>
	<keyword>ivermectin</keyword>
</DOC>